The CXCR4/SDF-1 Chemokine Receptor Axis: A New Target Therapeutic for Non-small Cell Lung Cancer.
Otsuka S, Bebb G.
University of Calgary, Calgary, Canada.
J Thorac Oncol. 2008 Dec;3(12):1379-1383.
[Credits go to Quackinvestor on the Y! Medarex board for digging this up]
Chemokines are proinflammatory chemoattractant cytokines that regulate cell trafficking and adhesion. The CXCR4 chemokine receptor and its ligand, stromal cell derived factor (SDF-1), constitute a chemokine/receptor axis that has attracted great interest because of an increasing understanding of its role in cancer, including lung cancer. The CXCR4/SDF-1 complex activates several pathways that mediate chemotaxis, migration and secretion of angiopoietic factors. Neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 monoclonal antibody in preclinical in vivo studies results in a significant decrease of non-small cell lung cancer metastases. Since anti-SDF-1/CXCR4 strategies have already been developed for use in combating human immunodeficiency virus infections, it is likely that these approaches will be used in clinical trials in non-small cell lung cancer in the very near future.
---------------------------
Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic
Posted on: Tuesday, 28 March 2006, 06:00 CST
OSAKA, Japan and PRINCETON, N.J., March 28 [2006]/PRNewswire-FirstCall/ -- Ono Pharmaceutical Co., Ltd. and Medarex, Inc. announced today that they have entered into a collaborative agreement to research and develop a fully human anti-SDF-1 antibody for the potential treatment of multiple indications. This is the second antibody development collaboration between Ono and Medarex. Anti-SDF-1 antibodies have been raised utilizing Medarex's UltiMAb Human Antibody Development System(R).
--------------------------
Back to the future:
At the R&D day in July it was stated that it is exected that MDX-1338 will enter into clinical development in H1-09. The initial safety study is planned to target relapsed or refractory leukimias. |
